The retail price for Lumryz (aromatase inhibitor) is $35,924.27 for a supply of 30 tablets [1]. This medication is used for the treatment of adults with paroxysmal nocturnal hemoglobinuria (PNH) [2].
How does Lumryz work?
Lumryz is a targeted therapy that inhibits the complement cascade, a part of the immune system. In PNH, the complement system can mistakenly attack and destroy red blood cells, leading to anemia and other complications [2]. Lumryz works by binding to complement protein C5, preventing it from being cleaved and thereby blocking the formation of the membrane attack complex (MAC), which is responsible for cell destruction [3].
How is Lumryz administered?
Lumryz is administered as a subcutaneous infusion. It is a long-acting C5 inhibitor, designed for less frequent dosing compared to other treatments [2].
What are the alternatives to Lumryz for PNH?
Other treatments for PNH include other complement inhibitors like Soliris (eculizumab) and Ultomiris (ravulizumab), which also target C5. Bone marrow transplant is another potential curative option for PNH, though it is a high-risk procedure [4].
When can generic versions of Lumryz become available?
The patent landscape for Lumryz and similar C5 inhibitors is complex and can influence the availability of generic or biosimilar versions. Information on specific patent expiry dates and potential market entry for generics can be found on specialized patent tracking websites [5]. For instance, DrugPatentWatch.com tracks patents for pharmaceutical products, which is a resource for understanding when market exclusivity might end [6].